Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma

22 Feb 2015

Abstract excerpt

Multiple mechanisms have been described that confer BRAF inhibitor resistance to melanomas, yet the basis of this resistance remains undefined in a sizable portion of patient samples. Here, we characterized samples from a set of patients with melanoma that included individuals at baseline diagnosis, on BRAF inhibitor treatment, and with resistant tumors at both the protein and RNA levels. Using RNA and DNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Computational Drug Discovery Methods
Share to HER2/EGFR in Cancer Research
Share to Melanoma and MAPK Pathways

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25705882
DOI: 10.1172/jci78954

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanomaPMID 25705882Read ↗

BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations.Semantic proximity Read ↗

Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic PlasticitySemantic proximity Read ↗

Multi-omics analysis delineates resistance mechanisms associated with BRAF inhibition in melanoma cells.Semantic proximity Read ↗

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor TherapySemantic proximity Read ↗

Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapySemantic proximity Read ↗

Genetic Layout of Melanoma Lesions Is Associated with BRAF/MEK-Targeted Therapy Resistance and Transcriptional Profiles.Semantic proximity Read ↗

PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic MelanomaSemantic proximity Read ↗

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.Semantic proximity Read ↗

Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review.Semantic proximity Read ↗

Divergent BRAF Inhibitor Resistance Mechanisms Revealed through Epigenetic Mapping.Semantic proximity Read ↗

Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanomaSemantic proximity Read ↗

Detecting mechanisms of acquired BRAF inhibitor resistance in melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.